Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Clinsup Forte is a fixed-dose combination vaginal suppository developed by Resilient Cosmeceuticals for the treatment of mixed vaginal infections. It contains three active ingredients: clindamycin phosphate, clotrimazole, and tinidazole. Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. Clotrimazole is an imidazole antifungal that inhibits the synthesis of ergosterol, an essential component of fungal cell membranes, by targeting lanosterol 14-alpha demethylase. Tinidazole is a nitroimidazole antimicrobial that causes DNA strand breakage in anaerobic bacteria and protozoa. This combination is designed for the syndromic management of vaginal discharge caused by bacterial vaginosis, vulvovaginal candidiasis, and trichomoniasis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clindamycin + clotrimazole + tinidazole.